Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD)
NCT05146154: Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Withdrawn
4
12
US
Imipenem/Cilastatin/Relebactam 1.25g, Recarbrio
University of Illinois at Chicago, Merck Sharp & Dohme LLC
Obesity, Critical Illness
06/23
01/24
NCT05561764: Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

Terminated
4
4
US
Imipenem/Cilastatin/Relebactam, Recarbrio
Hartford Hospital, Merck Sharp & Dohme LLC, Q2 Solutions, Connecticut Children's Medical Center, St. Christopher's Hospital for Children, University of Texas Southwestern Medical Center, University of Pittsburgh Medical Center, Indiana University Health Methodist Hospital, James Whitcomb Riley Hospital for Children
Cystic Fibrosis, Pneumonia, Bacterial
10/24
12/24
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, )

Recruiting
3
450
Europe, US, RoW
Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio
Evopoint Biosciences Inc.
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
04/25
12/25
MK-7655A-021, NCT03969901 / 2019-000338-20: Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection

Completed
2/3
115
Europe, US, RoW
IMI/REL, MK-7655A, Active Control
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Suspected or Documented Gram-negative Bacterial Infection
05/24
05/24
NCT04983901: PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Completed
2
100
US
Imipenem/Cilastatin/Relebactam, RECARBRIO™, Cefepime, Meropenem, Meropenem Trihydrate, Merrem I.V., SM-7338, Piperacillin-Tazobactam, PIPER/TAZO, Piperacillin/Tazobactam, Zosyn, Vancomycin, Daptomycin, Cubicin, LY146032, Linezolid, Zyvox
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
10/23
10/23
NCT04493151: Imipenem/Cilastatin/Relebactam PK in ECMO

Completed
1
8
US
Imipenem, Cilastatin and Relebactam, Recarbrio
Joseph L. Kuti, PharmD, Merck Sharp & Dohme LLC
Sepsis
05/23
06/23

Download Options